Cedric Hermans and Glenn Pierce On The Essential Role of A Positive Reinvestment Cycle in Hemophilia
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, shared on LinkedIn:
”Hemophilia stands out among rare diseases for its remarkable therapeutic progress, a success built on decades of innovation, scientific discovery, and investment.
From the cloning of FVIII and FIX genes to the arrival of gene therapy, each milestone has transformed lives.
Global advocacy by WFH, EAHAD, and NBDF has been key to ensuring access and safety.
Yet, sustaining this progress requires continued commitment and investment, so that every person with hemophilia can benefit from the full promise of science.”
Read the full article here.
Article: Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle
Authors: Cedric Hermans, Glenn F Pierce
Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.
-
Sep 23, 2026, 06:07Hoori Shahwar: Cerebral Venous Sinus Thrombosis Diagnosis and Management
-
Sep 23, 2026, 06:06Advancing Hemophilia Care and Patient Advocacy in Bangladesh – World Federation of Hemophilia
-
Sep 23, 2026, 05:54Bringing the Global Thrombosis and Haemostasis Community Together in 2027 – ISTH
-
Sep 23, 2026, 04:34David Akande: When Sickle Cell Crises Have No Clear Trigger
-
Sep 23, 2026, 04:13Jean Connors: Safety of Heparin Re-Exposure in Patients with Remote HIT
-
Sep 23, 2026, 04:09Beth Psaila: Applications Now Open for the Gordon Research Conference on Megakaryocytes and Platelets
-
Sep 23, 2026, 03:27Abbie Newton: How Better Data Can Reduce Platelet Wastage
-
Sep 23, 2026, 03:01Suvro Sankha Datta: Rapid Blood Group Genotyping Using Gold Oligo Nanonet Assembly
-
Sep 23, 2026, 02:55Asghar Muhammad: Exploring New Ways to Expand Blood Transfusion Compatibility